全文获取类型
收费全文 | 3517713篇 |
免费 | 279622篇 |
国内免费 | 27833篇 |
专业分类
耳鼻咽喉 | 50688篇 |
儿科学 | 102871篇 |
妇产科学 | 93309篇 |
基础医学 | 487196篇 |
口腔科学 | 100739篇 |
临床医学 | 330831篇 |
内科学 | 667694篇 |
皮肤病学 | 71211篇 |
神经病学 | 284259篇 |
特种医学 | 139733篇 |
外国民族医学 | 1464篇 |
外科学 | 521624篇 |
综合类 | 125869篇 |
现状与发展 | 83篇 |
一般理论 | 1324篇 |
预防医学 | 268839篇 |
眼科学 | 86816篇 |
药学 | 273174篇 |
333篇 | |
中国医学 | 23424篇 |
肿瘤学 | 193687篇 |
出版年
2021年 | 36346篇 |
2019年 | 32577篇 |
2018年 | 42119篇 |
2017年 | 33904篇 |
2016年 | 35826篇 |
2015年 | 44086篇 |
2014年 | 60603篇 |
2013年 | 81394篇 |
2012年 | 110793篇 |
2011年 | 118727篇 |
2010年 | 70865篇 |
2009年 | 65390篇 |
2008年 | 106061篇 |
2007年 | 112416篇 |
2006年 | 113651篇 |
2005年 | 111207篇 |
2004年 | 101871篇 |
2003年 | 98277篇 |
2002年 | 95925篇 |
2001年 | 154432篇 |
2000年 | 160431篇 |
1999年 | 138089篇 |
1998年 | 42015篇 |
1997年 | 38965篇 |
1996年 | 37171篇 |
1995年 | 35720篇 |
1994年 | 33038篇 |
1993年 | 29856篇 |
1992年 | 106883篇 |
1991年 | 102912篇 |
1990年 | 99736篇 |
1989年 | 96336篇 |
1988年 | 89352篇 |
1987年 | 87838篇 |
1986年 | 83595篇 |
1985年 | 79755篇 |
1984年 | 60109篇 |
1983年 | 51082篇 |
1982年 | 31009篇 |
1979年 | 56758篇 |
1978年 | 40075篇 |
1977年 | 34235篇 |
1976年 | 31652篇 |
1975年 | 34393篇 |
1974年 | 41854篇 |
1973年 | 40127篇 |
1972年 | 37984篇 |
1971年 | 35379篇 |
1970年 | 33384篇 |
1969年 | 31331篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
51.
目的:探讨姑息性胃切除联合术后化疗评分在腹膜转移的胃癌患者预后评估中的临床意义。方法:回顾性分析2010年1月至2016年12月7年间收治的287例发生腹膜转移的胃癌患者的临床病理资料。通过χ2检验分析评分与患者临床病理因素间的关系。通过Kaplan-Meier法绘制生存曲线,Log-rank检验比较患者生存率的差异;采用Cox比例风险回归模型对患者进行预后分析。结果:与评分中得分为2分和1分的患者相比,得分为0分的患者肿瘤侵润至T4b 期的患者较少[31%(18/58)比50.8%(63/124)、56.2%(59/105),P=0.039]。全组患者的中位生存时间仅为8.7月。对患者进行单因素预后分析结果显示,血清白蛋白浓度(≤40 g/L),腹水,腹膜转移范围较大,肿瘤T分期较晚,评分得分较高的患者预后较差(均P<0.05)。将上述因素纳入Cox多因素分析结果显示:评分[HR(95%CI):1.384(1.165~1.644),P=0.000],血清白蛋白浓度[HR(95%CI):0.759(0.593~0.971),P=0.028],肿瘤T分期[HR(95%CI):1.493(1.216~1.832),P=0.000]是患者预后的独立危险因素。结论:评分对于胃癌伴腹膜转移患者的预后生存评估具有重要的临床意义。 相似文献
52.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献
53.
Joshua J. Bear Heidi E. Kirsch Brian D. Berman Kevin E. Chapman Jason R. Tregellas 《Epileptic Disord》2020,22(3):291-299
Aims. Functional connectivity is providing new insights into the network nature of epilepsy with growing clinical applications. Our objective was to validate a novel magnetoencephalography‐based method to non‐invasively measure the epileptic network. Methods. We retrospectively identified pediatric and adult patients with refractory focal epilepsy who underwent pre‐surgical magnetoencephalography with subsequent intracranial electrographic monitoring. Magnetoencephalography tracings were visually reviewed, and interictal epileptiform discharges (“spikes”) were individually marked. We then evaluated differences in whole‐brain connectivity during brief epochs preceding the spikes and during the spikes using the Network‐Based Statistic to test differences at the network level. Results. In six patients with statistically‐significant network differences, we observed substantial overlap between the spike‐associated networks and electrographically active areas identified during intracranial monitoring (the spike‐associated network was 78% and 83% sensitive for intracranial electroencephalography‐defined regions in the irritative and seizure onset zones, respectively). Conclusion. These findings support the neurobiological validity of the spike‐associated network method. Assessment of spike‐associated networks has the potential to improve surgical planning in epilepsy surgery patients by identifying components of the epileptic network prior to implantation. 相似文献
54.
Rupa Narayan MD Traci M. Blonquist MS Ashkan Emadi MD PhD Robert P. Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S. Neuberg ScD Andrew M. Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L. McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A. Graubert MD Christina Bertoli MSN Jenna A. Moran MSN Meghan K. Bergeron MSN Julia E. Foster MSN Aura Y. Ramos BSN Tina T. Som BSN Megan K. Vartanian BSN RN Jennifer L. Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C. Wey PhD Jessica Rae BSN Frederic I. Preffer PhD Patricia Lesho BA Vu H. Duong MD Mason L. Mann BA Karen K. Ballen MD Christine Connolly BS Philip C. Amrein MD Amir T. Fathi MD 《Cancer》2020,126(6):1264-1273
55.
Brittney H. Cotta Margaret F. Meagher Aaron Bradshaw Stephen T. Ryan Gerant Rivera-Sanfeliz 《Expert review of anticancer therapy》2019,19(4):301-308
Introduction: Percutaneous renal mass biopsy has evolved over the last decade with improvements on previous pitfalls including low tissue yield, high non-diagnostic rates, and complications. As understanding of tumor biology and natural history of renal cortical neoplasms has improved, percutaneous renal mass biopsy is poised to have an expanding role in an area characterized by individualized management and refined risk stratification.
Areas covered: This review summarizes the evolution of renal mass biopsy to its current state with respect to outcomes, indications, and clinical guidelines.
Expert opinion: With improved understanding of differential biological potential of renal cortical neoplasms combined with technical improvements in diagnostic yield and accuracy, utilization of renal mass biopsy is becoming an important adjunct to patient care in a broad range of clinical scenarios, including active surveillance, thermal ablation, and use of primary systemic therapy in localized and advanced settings. 相似文献
56.
57.
58.
Xiying Fan Glen A. Bjerke Kent Riemondy Li Wang Rui Yi 《Molecular carcinogenesis》2019,58(12):2241-2253
MicroRNAs (miRNAs) play important roles in prostate cancer development. However, it remains unclear how individual miRNAs contribute to the initiation and progression of prostate cancer. Here we show that a basal layer‐enriched miRNA is required for prostate tumorigenesis. We identify miR‐205 as the most highly expressed miRNA and enriched in the basal cells of the prostate. Although miR‐205 is not required for normal prostate development and homeostasis, genetic deletion of miR‐205 in a Pten null tumor model significantly compromises tumor progression and does not promote metastasis. In Pten null basal cells, loss of miR‐205 attenuates pAkt levels and promotes cellular senescence. Furthermore, although overexpression of miR‐205 in prostate cancer cells with luminal phenotypes inhibits cell growth in both human and mouse, miR‐205 has a minimal effect on the growth of a normal human prostate cell line. Taken together, we have provided genetic evidence for a requirement of miR‐205 in the progression of Pten null‐induced prostate cancer. 相似文献
59.
60.
Tonya J.H. White 《Journal of the American Academy of Child and Adolescent Psychiatry》2019,58(11):1042-1050